Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Prime Medicine, Inc. (PRME)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.97+9.23%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PRME yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund operations into 2027 with current cash | It aims to fund operations into 2027 with current cash. | Intact | cash reserves fall below operating expense needs before end of 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology business, not a proven earnings compounder. The long-term thesis is in a watch state: management is advancing its programs, but the evidence remains mixed and the business is loss-making.
PRME is valued at a premium to peers, with valuation partly reflecting the potential of future programs. Confidence in that valuation view is low, and the evidence does not show that the market has priced in a broader stack of weak performance and turbulence.
Near term, the latest earnings were in line after an earlier miss, while performance remains below the industry cohort. Management is progressing PM577a, PM647, and PM359 toward stated clinical and regulatory milestones, but cash declined from late 2025 to the second quarter of 2026 as operations continued to burn cash. Management says available cash funds operations into 2027, though a guidance cut or weaker employment data could add pressure.
Over the next year, the thesis hinges on clinical progress and whether management meets the stated timelines, including initial data anticipated in 2027 and a planned PM359 filing in the first half of 2027. It also depends on cash runway and upcoming guidance; stronger results from healthcare bellwethers could support sector momentum, while weakening employment data could weigh on healthcare names.
For the next 1 to 3 years, PRME remains a high-risk, loss-making clinical-stage story with meaningful program milestones but limited evidence of established financial strength. The thesis rests on execution, regulatory progress, and funding operations into 2027. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Prime Medicine, Inc.'s published investment case. The stated target is EPS loss narrows to better than -$0.84 by FY27. |
| Intact |
| EPS loss worsens beyond -$0.99 in FY26 or fails to improve in FY27 |
Diluted EPS: $-0.24 per share FY2026-Q2; GAAP. Published target: EPS loss narrows to better than -$0.84 by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-0.24 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance Prime Editing pipeline targeting genetic disorders and cancers | Prime Medicine leads in precise gene editing technology. | Improving | significant delays or failures in key clinical programs | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.84 → $-0.93 · observed estimates
$0.02B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-07-25 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-07-26 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-07-27 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-07-28 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-07-29 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-07-30 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-07-31 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-01 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-02 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-03 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-04 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-08-05 | $-0.84 | $18,388,160 | 10 / 11 |
| 2026-08-06 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-07 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-08 | $-0.91 | $8,049,400 | 9 / 7 |
| 2026-08-09 | $-0.91 | $8,049,400 | 9 / 7 |
| 2026-08-10 | $-0.91 | $8,049,400 | 9 / 7 |
| 2026-08-12 | $-0.89 | $11,578,350 | 9 / 11 |
| 2026-08-13 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-14 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-15 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-16 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-17 | $-0.88 | $21,022,484 | 8 / 8 |
| 2026-08-18 | $-0.88 | $21,022,484 | 8 / 9 |
| 2026-08-19 | $-0.88 | $21,022,484 | 8 / 9 |
| 2026-08-20 | $-0.92 | $10,783,122 | 8 / 9 |
| 2026-08-21 | $-0.92 | $10,783,122 | 9 / 10 |
| 2026-08-22 | $-0.92 | $10,783,122 | 9 / 10 |
| 2026-08-23 | $-0.92 | $10,783,122 | 9 / 10 |
| 2026-08-24 | $-0.92 | $10,783,122 | 9 / 10 |
| 2026-08-25 | $-0.93 | $10,561,343 | 9 / 10 |
| 2026-08-26 | $-0.93 | $10,561,343 | 9 / 10 |
| 2026-08-27 | $-0.93 | $10,561,343 | 9 / 10 |
| 2026-08-28 | $-0.93 | $10,561,343 | 9 / 10 |
| 2026-08-29 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-08-30 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-08-31 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-01 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-02 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-03 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-04 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-05 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-06 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-07 | $-0.93 | $10,561,343 | 10 / 11 |
| 2026-09-08 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-09 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-10 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-11 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-12 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-13 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-14 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-15 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-16 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-17 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-18 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-19 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-20 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-21 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-22 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-23 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-24 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-25 | $-0.92 | $10,561,343 | 10 / 11 |
| 2026-09-26 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-09-27 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-09-28 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-09-29 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-09-30 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-01 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-02 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-03 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-04 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-05 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-06 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-07 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-08 | $-0.92 | $10,545,959 | 10 / 10 |
| 2026-10-09 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-10 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-11 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-12 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-13 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-14 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-15 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-16 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-17 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-18 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-19 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-20 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-21 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-22 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-23 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-24 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-25 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-26 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-27 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-28 | $-0.92 | $11,041,455 | 10 / 10 |
| 2026-10-29 | $-0.93 | $11,041,455 | 10 / 10 |
| 2026-10-30 | $-0.93 | $11,041,455 | 10 / 10 |
| 2026-10-31 | $-0.93 | $11,041,455 | 10 / 10 |
| 2026-11-01 | $-0.93 | $11,041,455 | 10 / 10 |
| 2026-11-02 | $-0.93 | $11,041,455 | 10 / 10 |
| 2026-11-03 | $-0.93 | $11,041,455 | 10 / 10 |
| 2026-11-04 | $-0.93 | $11,041,455 | 10 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.